Abstracts tagged "Disease Activity and systemic lupus erythematosus (SLE)"

Abstract Number: 2920 • 2015 ACR/ARHP Annual Meeting
Time to Recovery of Individual Lupus Manifestations on Standard of Care Treatment
Zahi Touma¹, Dafna Gladman¹, Jiandong Su¹ and Murray Urowitz^2,3, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Musculoskeletal, dermal and renal systems are the most commonly represented systems in lupus clinical trials. Thus, it is very important to study the time…
Abstract Number: 2928 • 2015 ACR/ARHP Annual Meeting
Persistent Disease Activity over Time in a Large Canadian Cohort of Prevalent Lupus Patients
Christine A. Peschken¹, Willy Wynant², Michal Abrahamowicz³, Janet E. Pope⁴, Earl Silverman⁵, Amyn Sayani⁶, Sandra Iczkovitz⁶, Jorge A. Ross⁶, Christian Pineau⁷, C Douglas Smith⁸, Marie Hudson⁷, Michel Zummer⁹, Lori B. Tucker¹⁰, Deborah M. Levy¹¹, Gaëlle Chédeville¹², Adam M. Huber¹³, Hector Arbillaga¹⁴, Carol Hitchon¹⁵, Paul R. Fortin¹⁶ and CaNIOS 1000 Faces Investigators, ¹Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ²McGill University, Quebec, QC, Canada, ³Department of Epidemiology and Biostatistics., McGill University, Montreal, QC, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁶Medical Affairs, GlaxoSmithKline, Mississauga, ON, Canada, ⁷Medicine, McGill University, Montreal, QC, Canada, ⁸The Arthritis Centre, TOH Riverside Campus, Ottawa, ON, Canada, ⁹Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ¹⁰Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ¹¹Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹²Rheumatology, McGill University, Montreal, QC, Canada, ¹³Pediatric rheumatology, IWK Health Centre, Halifax, NS, Canada, ¹⁴Calgary Rheumatology, Calgary, AB, Canada, ¹⁵University of Manitoba, Winnipeg, MB, Canada, ¹⁶Medicine, CHU de Québec - Université Laval, Québec, QC, Canada
Background/Purpose: Treatment of systemic lupus erythematosus (SLE) aims at controlling disease activity to prevent damage. In a large multi-centre cohort of prevalent SLE patients we…
Abstract Number: 765 • 2015 ACR/ARHP Annual Meeting
Clinical Improvements in Systemic Lupus Erthematosus Are Correlated to Cellular and Soluble Biomarkers in Classical Complement Pathway
Chaim Putterman¹, Jill P. Buyon², Richard Furie³, Rosalind Ramsey-Goldman⁴, Kenneth Kalunian⁵, John Conklin⁶, Tyler O'Malley⁷, Derren Barken⁸ and Thierry Dervieux⁷, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²NYU School of Medicine, New York, NY, ³NSLIJHS, Lake Success, NM, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵UCSD School of Medicine, La Jolla, CA, ⁶1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁷Research and Development, Exagen Diagnostics, Vista, CA, ⁸Exagen Diagnostics, Vista, CA
Background/Purpose : There is a need to identify biomarkers that track disease response in systemic lupus erythematosus (SLE). The value of various biomarkers in monitoring…
Abstract Number: 714 • 2014 ACR/ARHP Annual Meeting
The Validity of Patient and Physician Global Disease Activity Assessments of Systemic Lupus Erythematosus: Results from the Lupus Activity Scoring Tool (LAST) As Compared to the Selena Sledai (SS) Modification Multicentre Study
Majed Khraishi¹, Rana Aslanov², Sanjay Dixit³, Ramin Yazdani⁴, Vandana Ahluwalia⁵ and Sarah Khraishi⁶, ¹Nexus Clinical Research, St John's, NF, Canada, ²Clinical Epidemiology Department, Faculty of Medicine, Memorial University of Newfoundland, St.John's, NF, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Rheumatology, St. Clare' Mercy Hospital, St. John's, NF, Canada, ⁵Rheumatology, William Osler Health Center, Brampton, ON, Canada, ⁶NL Research Technologies (NLRT), St. John's, NF, Canada
Background/Purpose In our centre, new tools for the assessment of SLE activity: the Lupus Activity Scoring Tool (LAST) and Clinical Lupus Activity Scoring Tool (C-LAST)…
Abstract Number: 2541 • 2013 ACR/ARHP Annual Meeting
Disease Activity Does Not Improve Significantly In One System and Worsen In Another System
Zahi Touma¹, Dafna D. Gladman² and Murray B. Urowitz², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematous Disease Activity Index-2000 (SLEDAI-2K) is a global index that describes disease activity overall in 9 systems. The use of multiple measures…
Abstract Number: 2518 • 2013 ACR/ARHP Annual Meeting
Only BAFF mRNA, Not BAFF Protein Level In Blood, Is Associated With SLE Activity Over One Year
Eric Zollars¹, Hong Fang², Jadwiga Bienkowska³, Julie Czerkowicz⁴, Ann Ranger⁴, Norm Allaire⁵, Alice Thai⁴, Jeff Browning⁶, Laurence S. Magder⁷ and Michelle Petri², ¹Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Biogen Idec Inc, Cambridge, MA, ⁵Biogen Idec Inc., Cambridge, MA, ⁶Boston University School of Medicine, Boston, MA, ⁷Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: B-cell–activating factor (BAFF; also known as B lymphocyte stimulator or BLyS) is a prominent factor in the selection and survival of B cells. BAFF…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].